Jersey City, N.J.-based SCYNEXIS announced positive results from the biotechnology company’s second interim efficacy analysis of the Phase III open-label FURI study.

Cidara Therapeutics Inc. announced that data from studies of the biotechnology company’s lead antifungal rezafungin will be presented at the 2019 Transplantation and Cellular Therapy (TCT) Meeting of ASBMT and CIBMTR to be held in Houston from Feb. 20-24.